Spots Global Cancer Trial Database for renal dialysis
Every month we try and update this database with for renal dialysis cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
Safety, Tolerability and Efficacy of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparathyroidism | NCT01254565 | Secondary Hyper... | Etelcalcetide Placebo | 18 Years - | KAI Pharmaceuticals | |
Open-label Study to Assess the Long-term Safety and Efficacy of Etelcalcetide (Also Known as AMG 416 or KAI-4169) in Patients With Secondary Hyperparathyroidism | NCT01576146 | Secondary Hyper... | Etelcalcetide | 18 Years - | KAI Pharmaceuticals | |
Safety, Tolerability and Pharmacokinetics of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparathyroidism | NCT01134562 | Hyperparathyroi... | Placebo Etelcalcetide | 18 Years - | KAI Pharmaceuticals | |
Open-label Study to Assess the Long-term Safety and Efficacy of Etelcalcetide (Also Known as AMG 416 or KAI-4169) in Patients With Secondary Hyperparathyroidism | NCT01576146 | Secondary Hyper... | Etelcalcetide | 18 Years - | KAI Pharmaceuticals | |
Safety, Tolerability and Pharmacokinetics of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparathyroidism | NCT01134562 | Hyperparathyroi... | Placebo Etelcalcetide | 18 Years - | KAI Pharmaceuticals |